Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, Obesity and Metabolism

Volumn 13, Issue 6, 2011, Pages 523-532

  Nowicki, M ^a   Rychlik, I ^b   Haller, H ^c   Warren, M L ^d   Suchower, L ^e   Gause Nilsson, I ^f  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CHARLES UNIVERSITY   (Czech Republic)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Physician's East PA   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Dipeptidyl peptidase 4 inhibitor; End stage renal disease; Glycaemic control; Renal impairment; Saxagliptin; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; URINARY TRACT INFECTION;

EID: 79955048927     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01382.x     Document Type: Article

References (21)

1. United States Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
2. Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008; 82(Suppl. 1): S75-79.
3. Fox CS, Muntner P. Trends in diabetes, high cholesterol, and hypertension in chronic kidney disease among U.S. adults: 1988-1994 to 1999-2004. Diabetes Care 2008; 31: 1337-1342.
4. Albright A, Burrows NR, Jordan R, Williams DE. The kidney disease initiative and the division of diabetes translation at the Centers for Disease Control and Prevention. Am J Kidney Dis 2009; 53(3 Suppl. 3): S121-125.
5. United States Renal Data System. The Concise 2009 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009. Available from URL: Accessed 16 July 2010.
6. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
7. Odegard PS, Setter SM, Neumiller JJ. Considerations for the pharmacological treatment of diabetes in older adults. Diabetes Spectrum 2007; 20: 239-247.
8. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009; 26: 249-262.
9. Kirby M, Yu DMT, O'Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118: 31-41.
10. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb/Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2011.
11. Rosenstock J, Aguilar-Salinas C, Klein E et al. Effect of saxagliptin monotherapy in treatment-naÏve patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401-2411.
12. Jadzinsky M, Pfützner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
13. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
14. Hollander P, Li J, Allen E, Chen R, for the CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-4819.
15. DeFronzo RA, Hissa M, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-1655.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
17. Levey AS, Coresh J, Greene T. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
18. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol 2010; 21: 383-385.
19. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009; 32: 1137-1142.
20. Mirani M, Berra C, Finazzi S et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther 2010; 12: 749-753.
21. Bristol-Myers Squibb/AstraZeneca. Safety and Efficacy Study of Saxagliptin Added to Insulin Alone or to Insulin Taken with Metformin. In: ClinicalTrials.gov (Internet). National Library of Medicine (US), Bethesda, MD. Available from URL: NLM Identifier: NCT00757588. Accessed 19 October 2010.